The historic rise of Viagra has long been a symbol of pharmaceutical success, yet its position within the broader sector now presents questions about potential gains. Copycat versions are diminishing market share, prompting worries that investing in companies heavily reliant to Viagra's previous position could be a speculative decision , especially